Galapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.
BioNTech pulls in massive €290m financing
Latest NewsIt is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis launches €9m Nasdaq IPO
Latest NewsBiophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
€30m for Evotec cancer spin-out
Latest NewsGerman biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
Partnership in pursuit of new antibiotics class
Latest NewsA new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
Jens-Peter Marschner joins Zelluna
AppointmentsZelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.
Bioeconomy: just a way to set up a smarter agriculture?
BackgroundOutgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.
Drug puts CAR T activity on hold
Latest NewsGerman researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.
Biotech company Galapagos improves high-content screening (HCS) in scleroderma with IN Carta Phenoglyphs image analysis
Sponsored PublicationsGalapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.
License deal in oncolytic virotherapies
Latest NewsOncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
Helena Strigård becomes CEO of Swedenbio
AppointmentsSwedenbio’s Board has appointed Helena Strigård as the new CEO. Strigård will take up the position on September 1 and replace Jonas Ekstrand,